

Thomas P C Dorlo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8653884/publications.pdf>

Version: 2024-02-01

88
papers

2,785
citations

201674

27
h-index

189892

50
g-index

89
all docs

89
docs citations

89
times ranked

3301
citing authors

#	ARTICLE	IF	CITATIONS
1	Development and validation of an HPLC-MS/MS method for the quantification of the anti-leishmanial drug miltefosine in human skin tissue. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2022, 207, 114402.	2.8	9
2	Population Pharmacokinetic Modelling to Support the Evaluation of Preclinical Pharmacokinetic Experiments with Lorlatinib. <i>Journal of Pharmaceutical Sciences</i> , 2022, 111, 495-504.	3.3	2
3	Pharmacokinetic/Pharmacodynamic Modelling of Allopurinol, its Active Metabolite Oxypurinol, and Biomarkers Hypoxanthine, Xanthine and Uric Acid in Hypoxic-Ischemic Encephalopathy Neonates. <i>Clinical Pharmacokinetics</i> , 2022, 61, 321-333.	3.5	3
4	An update on the clinical pharmacology of miltefosine in the treatment of leishmaniasis. <i>International Journal of Antimicrobial Agents</i> , 2022, 59, 106459.	2.5	32
5	No evidence for cardiotoxicity of miltefosine. <i>Anais Brasileiros De Dermatologia</i> , 2022, , .	1.1	0
6	Longitudinal nonlinear mixed effects modeling of <scp>EGFR</scp> mutations in <scp>ctDNA</scp> as predictor of disease progression in treatment of <scp>EGFR</scp>â€ˆmutant nonâ€ˆsmall cell lung cancer. <i>Clinical and Translational Science</i> , 2022, 15, 1916-1925.	3.1	8
7	Predictiveness of the Human-CYP3A4-Transgenic Mouse Model (Cyp3aXAV) for Human Drug Exposure of CYP3A4-Metabolized Drugs. <i>Pharmaceuticals</i> , 2022, 15, 860.	3.8	3
8	Development and validation of a high-performance liquid chromatography tandem mass spectrometry method for the quantification of the antiparasitic and antifungal drug amphotericin B in human skin tissue. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2022, 1206, 123354.	2.3	3
9	Population Pharmacokinetics of Intracellular 5-Fluorouridine 5â€™-Triphosphate and its Relationship with Hand-and-Foot Syndrome in Patients Treated with Capecitabine. <i>AAPS Journal</i> , 2021, 23, 23.	4.4	2
10	Population Pharmacokinetics of Docetaxel, Paclitaxel, Doxorubicin and Epirubicin in Pregnant Women with Cancer: A Study from the International Network of Cancer, Infertility and Pregnancy (INCIP). <i>Clinical Pharmacokinetics</i> , 2021, 60, 775-784.	3.5	15
11	Blood Parasite Load as an Early Marker to Predict Treatment Response in Visceral Leishmaniasis in Eastern Africa. <i>Clinical Infectious Diseases</i> , 2021, 73, 775-782.	5.8	13
12	Low antileishmanial drug exposure in HIV-positive visceral leishmaniasis patients on antiretrovirals: an Ethiopian cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 1258-1268.	3.0	8
13	Investigating the influence of relevant pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of orally administered docetaxel combined with ritonavir. <i>Pharmacogenomics Journal</i> , 2021, 21, 336-345.	2.0	0
14	Worse capecitabine treatment outcome in patients with a low skeletal muscle mass is not explained by altered pharmacokinetics. <i>Cancer Medicine</i> , 2021, 10, 4781-4789.	2.8	6
15	Geographical Variability in Paromomycin Pharmacokinetics Does Not Explain Efficacy Differences between Eastern African and Indian Visceral Leishmaniasis Patients. <i>Clinical Pharmacokinetics</i> , 2021, 60, 1463-1473.	3.5	8
16	Relapsing leishmanial arthritis: report of a tricky localization and evidence of miltefosine diffusion in synovial fluid. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2740-2741.	3.0	1
17	Influence of Malnutrition on the Pharmacokinetics of Drugs Used in the Treatment of Poverty-Related Diseases: A Systematic Review. <i>Clinical Pharmacokinetics</i> , 2021, 60, 1149-1169.	3.5	13
18	Toxicity of pemetrexed during renal impairment explainedâ€ˆ”Implications for safe treatment. <i>International Journal of Cancer</i> , 2021, 149, 1576-1584.	5.1	9

#	ARTICLE	IF	CITATIONS
19	A physiologically based pharmacokinetic (PBPK) model to describe organ distribution of ⁶⁸ Ga-DOTATATE in patients without neuroendocrine tumors. <i>EJNMMI Research</i> , 2021, 11, 73.	2.5	7
20	A Semi-Mechanistic Population Pharmacokinetic/Pharmacodynamic Model of Bortezomib in Pediatric Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. <i>Clinical Pharmacokinetics</i> , 2020, 59, 207-216.	3.5	3
21	Characterizing the non-linear pharmacokinetics of miltefosine in paediatric visceral leishmaniasis patients from Eastern Africa. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3260-3268.	3.0	9
22	Evaluation of Extrapolation Methods to Predict Trough Concentrations to Guide Therapeutic Drug Monitoring of Oral Anticancer Drugs. <i>Therapeutic Drug Monitoring</i> , 2020, 42, 532-539.	2.0	15
23	Population pharmacokinetic analysis of nanoparticle-bound and free camptothecin after administration of NLG207 in adults with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 86, 475-486.	2.3	10
24	Skin tissue sample collection, sample homogenization, and analyte extraction strategies for liquid chromatographic mass spectrometry quantification of pharmaceutical compounds. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020, 191, 113590.	2.8	12
25	Clinical Trial Simulation To Optimize Trial Design for Fludarabine Dosing Strategies in Allogeneic Hematopoietic Cell Transplantation. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2020, 9, 272-281.	2.5	6
26	Pharmacokinetic Targets for Therapeutic Drug Monitoring of Small Molecule Kinase Inhibitors in Pediatric Oncology. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 494-505.	4.7	17
27	Quantification of the pharmacokinetic-toxicodynamic relationship of oral docetaxel co-administered with ritonavir. <i>Investigational New Drugs</i> , 2020, 38, 1526-1532.	2.6	1
28	Highly sensitive UPLC-MS/MS method for the quantification of paromomycin in human plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020, 185, 113245.	2.8	8
29	Population Pharmacokinetics of MCLA-128, a HER2/HER3 Bispecific Monoclonal Antibody, in Patients with Solid Tumors. <i>Clinical Pharmacokinetics</i> , 2020, 59, 875-884.	3.5	13
30	Pharmacokinetics, Safety, and Efficacy of an Allometric Miltefosine Regimen for the Treatment of Visceral Leishmaniasis in Eastern African Children: An Open-label, Phase II Clinical Trial. <i>Clinical Infectious Diseases</i> , 2019, 68, 1530-1538.	5.8	31
31	Does Older Age Lead to Higher Risk for Neutropenia in Patients Treated with Paclitaxel?. <i>Pharmaceutical Research</i> , 2019, 36, 163.	3.5	5
32	Exposure to Docetaxel in the Elderly Patient Population: a Population Pharmacokinetic Study. <i>Pharmaceutical Research</i> , 2019, 36, 181.	3.5	4
33	Systematic Review of Host-Mediated Activity of Miltefosine in Leishmaniasis through Immunomodulation. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	30
34	1662. Pushing the Dose: Miltefosine Treatment for a Supersized American with Cutaneous Leishmaniasis. <i>Open Forum Infectious Diseases</i> , 2019, 6, S608-S608.	0.9	0
35	Fludarabine exposure in the conditioning prior to allogeneic hematopoietic cell transplantation predicts outcomes. <i>Blood Advances</i> , 2019, 3, 2179-2187.	5.2	42
36	Impact of Older Age on the Exposure of Paclitaxel: a Population Pharmacokinetic Study. <i>Pharmaceutical Research</i> , 2019, 36, 33.	3.5	6

#	ARTICLE	IF	CITATIONS
37	Population Pharmacokinetics of Fludarabine in Children and Adults during Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation. <i>Clinical Pharmacokinetics</i> , 2019, 58, 627-637.	3.5	41
38	Pharmacodynamic modeling of cardiac biomarkers in breast cancer patients treated with anthracycline and trastuzumab regimens. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2018, 45, 431-442.	1.8	18
39	Individualized Fludarabine Dosing for Predictable Immune Reconstitution and Increased Survival Chances after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S306-S307.	2.0	1
40	Clinical Pharmacokinetics of Systemically Administered Antileishmanial Drugs. <i>Clinical Pharmacokinetics</i> , 2018, 57, 151-176.	3.5	55
41	Safe mass drug administration for neglected tropical diseases. <i>The Lancet Global Health</i> , 2018, 6, e1054-e1055.	6.3	5
42	Simultaneous population pharmacokinetic modelling of plasma and intracellular PBMC miltefosine concentrations in New World cutaneous leishmaniasis and exploration of exposureâ€“response relationships. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2104-2111.	3.0	11
43	Population Pharmacokinetics of Artemether, Dihydroartemisinin, and Lumefantrine in Rwandese Pregnant Women Treated for Uncomplicated Plasmodium falciparum Malaria. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	15
44	Macrophage Activation Marker Neopterin: A Candidate Biomarker for Treatment Response and Relapse in Visceral Leishmaniasis. <i>Frontiers in Cellular and Infection Microbiology</i> , 2018, 8, 181.	3.9	15
45	Pharmacokinetics of Miltefosine in Children and Adults with Cutaneous Leishmaniasis. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	41
46	Volumetric absorptive microsampling (VAMS) as an alternative to conventional dried blood spots in the quantification of miltefosine in dried blood samples. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 135, 160-166.	2.8	65
47	Letter by Dorlo Regarding Article, â€œAcupuncture Therapy and Incidence of Depression After Strokeâ€. <i>Stroke</i> , 2017, 48, e231.	2.0	0
48	Lack of Clinical Pharmacokinetic Studies to Optimize the Treatment of Neglected Tropical Diseases: A Systematic Review. <i>Clinical Pharmacokinetics</i> , 2017, 56, 583-606.	3.5	27
49	Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa: a population pharmacokinetic/pharmacodynamic study. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 3131-3140.	3.0	23
50	Immunomodulatory Therapy of Visceral Leishmaniasis in Human Immunodeficiency Virus-Coinfected Patients. <i>Frontiers in Immunology</i> , 2017, 8, 1943.	4.8	32
51	From Bench to Bedside: Development and Optimization of Clinical Therapies for Visceral Leishmaniasis. <i>RSC Drug Discovery Series</i> , 2017, , 37-54.	0.3	2
52	Treatment of visceral leishmaniasis: pitfalls and stewardship. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 777-778.	9.1	4
53	Validation and Clinical Evaluation of a Novel Method To Measure Miltefosine in Leishmaniasis Patients Using Dried Blood Spot Sample Collection. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 2081-2089.	3.2	17
54	Pharmacokinetics and pharmacodynamics of oleylphosphocholine in a hamster model of visceral leishmaniasis. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1892-1898.	3.0	7

#	ARTICLE	IF	CITATIONS
55	Predictable threats to public health through delaying universal access to innovative medicines for hepatitis C: a pharmaceutical standpoint. <i>Tropical Medicine and International Health</i> , 2016, 21, 1490-1495.	2.3	3
56	Poverty-Related Diseases College: a virtual African-European network to build research capacity. <i>BMJ Global Health</i> , 2016, 1, e000032.	4.7	3
57	Dose Reduction of Caspofungin in Intensive Care Unit Patients with Child Pugh B Will Result in Suboptimal Exposure. <i>Clinical Pharmacokinetics</i> , 2016, 55, 723-733.	3.5	35
58	Functional Validation of ABCA3 as a Miltefosine Transporter in Human Macrophages. <i>Journal of Biological Chemistry</i> , 2016, 291, 9638-9647.	3.4	9
59	Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial. <i>PLoS Neglected Tropical Diseases</i> , 2016, 10, e0004880.	3.0	66
60	Population pharmacokinetics of levamisole in children with steroid-sensitive nephrotic syndrome. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 242-252.	2.4	12
61	Quantification of miltefosine in peripheral blood mononuclear cells by high-performance liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2015, 998-999, 57-62.	2.3	13
62	Assessment of blood-brain barrier penetration of miltefosine used to treat a fatal case of granulomatous amebic encephalitis possibly caused by an unusual <i>Balamuthia mandrillaris</i> strain. <i>Parasitology Research</i> , 2015, 114, 4431-4439.	1.6	26
63	Systematic Review of Biomarkers To Monitor Therapeutic Response in Leishmaniasis. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 1-14.	3.2	62
64	Failure of Miltefosine Treatment for Visceral Leishmaniasis in Children and Men in South-East Asia. <i>PLoS ONE</i> , 2014, 9, e100220.	2.5	66
65	Failure of Miltefosine in Visceral Leishmaniasis Is Associated With Low Drug Exposure. <i>Journal of Infectious Diseases</i> , 2014, 210, 146-153.	4.0	110
66	Safety and Efficacy of Single Dose versus Multiple Doses of AmBisome® for Treatment of Visceral Leishmaniasis in Eastern Africa: A Randomised Trial. <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e2613.	3.0	71
67	LeishMan Recommendations for Treatment of Cutaneous and Mucosal Leishmaniasis in Travelers, 2014. <i>Journal of Travel Medicine</i> , 2014, 21, 116-129.	3.0	110
68	Different liposomal amphotericin B formulations for visceral leishmaniasis. <i>The Lancet Global Health</i> , 2014, 2, e449.	6.3	4
69	Please, let not Western quackery replace traditional medicine in Africa. <i>Tropical Medicine and International Health</i> , 2013, 18, 242-244.	2.3	2
70	Reply to Arya and Agarwal. <i>Clinical Infectious Diseases</i> , 2013, 57, 917-918.	5.8	1
71	Increasing Failure of Miltefosine in the Treatment of Kala-azar in Nepal and the Potential Role of Parasite Drug Resistance, Reinfection, or Noncompliance. <i>Clinical Infectious Diseases</i> , 2013, 56, 1530-1538.	5.8	276
72	Adherence to miltefosine treatment for visceral leishmaniasis under routine conditions in Nepal. <i>Tropical Medicine and International Health</i> , 2013, 18, 179-187.	2.3	18

#	ARTICLE	IF	CITATIONS
73	The global impact of Indian generics on access to health. <i>Indian Journal of Medical Ethics</i> , 2013, 10, 118-20.	0.4	5
74	A Poor-Quality Generic Drug for the Treatment of Visceral Leishmaniasis: A Case Report and Appeal. <i>PLoS Neglected Tropical Diseases</i> , 2012, 6, e1544.	3.0	28
75	Lopinavir/ritonavir significantly influences pharmacokinetic exposure of artemether/lumefantrine in HIV-infected Ugandan adults. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 1217-1223.	3.0	43
76	Optimal Dosing of Miltefosine in Children and Adults with Visceral Leishmaniasis. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 3864-3872.	3.2	84
77	Translational pharmacokinetic modelling and simulation for the assessment of duration of contraceptive use after treatment with miltefosine. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 1996-2004.	3.0	29
78	Characterization and identification of suspected counterfeit miltefosine capsules. <i>Analyst, The</i> , 2012, 137, 1265.	3.5	38
79	Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 2576-2597.	3.0	605
80	Universal access to quality medicines: prioritisation of a-priori solutions. <i>Lancet Infectious Diseases, The</i> , 2012, 12, 829-830.	9.1	1
81	Commentary: Substandard medicines are the priority for neglected tropical diseases. <i>BMJ, The</i> , 2012, 345, e7518-e7518.	6.0	9
82	Safety and Efficacy of miltefosine alone and in combination with sodium stibogluconate and liposomal amphotericin B for the treatment of primary visceral leishmaniasis in East Africa: study protocol for a randomized controlled trial. <i>Trials</i> , 2011, 12, 166.	1.6	43
83	Dynamics of Parasite Clearance in Cutaneous Leishmaniasis Patients Treated with Miltefosine. <i>PLoS Neglected Tropical Diseases</i> , 2011, 5, e1436.	3.0	29
84	Severe encephalopathy and polyneuropathy induced by dichloroacetate. <i>Journal of Neurology</i> , 2010, 257, 2099-2100.	3.6	27
85	Comment on: Cutaneous and mucocutaneous leishmaniasis in Tigray, northern Ethiopia: clinical aspects and therapeutic concerns. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2010, 104, 84-85.	1.8	5
86	Development and validation of a quantitative assay for the measurement of miltefosine in human plasma by liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2008, 865, 55-62.	2.3	50
87	Pharmacokinetics of Miltefosine in Old World Cutaneous Leishmaniasis Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 2855-2860.	3.2	141
88	Pentamidine Dosage: A Base/Salt Confusion. <i>PLoS Neglected Tropical Diseases</i> , 2008, 2, e225.	3.0	28